Doximity Raises Full-Year Guidance as AI Scribe Surges Tenfold, Clinical AI Tops Safety Study
Doximity (NYSE: DOCS) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Revenue was $156.6M, up 7% and above consensus $151.7M; adjusted EBITDA was $74.8M. The company raised full-year revenue guidance to $671M-$681M and said Doximity Scribe active users rose tenfold and its Ask ranked first in the NOHARM clinical AI safety study. DOCS shares jumped in premarket.
How this was made
The 30-second read
Why it matters
The article frames a market reset: investors had discounted AI spend, but the company now pairs raised full-year guidance with quantified AI adoption and an independent safety benchmark ranking for its clinical AI assistant.
Market read
DOCS is repriced on a fresh earnings-and-guidance package plus AI adoption and safety validation, making this a high-volatility, catalyst-driven setup into the next trading session.
What to watch
Operating cash flow and free cash flow both fell year over year due to an “AI investment year,” and Q2 revenue guidance midpoint is slightly below some forecasts at the high end.
Background
Doximity is a physician-networking platform expanding into HIPAA-compliant clinical AI tools (Scribe and Ask) and monetizing via enterprise deployments and AI Search tied to physician intent.
Ticker impact
Doximity shares surged premarket after it raised FY revenue guidance and reported a tenfold jump in Scribe users plus top NOHARM safety ranking.
Near-term upside bias with elevated volatility, as the market reprices Doximity from ad platform to clinical AI franchise; follow-through depends on whether Q2 guidance and cash flow stabilize.
The text provides fresh guidance ranges, quantified AI engagement (tenfold Scribe user growth), and a specific independent study ranking for Doximity Ask, all tied to the same premarket move.
Market effects
Supports the narrative that clinical AI with physician-in-the-loop review can clear safety scrutiny, potentially benefiting other health AI vendors competing on trust and validation.
US healthcare IT and digital health sentiment likely improves as investors reward measurable clinical AI safety outcomes.
Limited direct global read-through, but it reinforces international interest in regulated, safety-benchmarked AI in healthcare.
Counterpoint
The NOHARM benchmark is not yet peer-reviewed and a direct competitor (OpenEvidence) publicly challenged the methodology, which could cap how durable the safety-premium rerating is.
Key entities
- companyDoximity
Physician-networking company whose DOCS shares surged on raised guidance and AI milestones, including NOHARM safety study performance.
- productDoximity Scribe
HIPAA-compliant ambient note-taking tool; reported tenfold increase in active users in July vs. prior year.
- productDoximity Ask
HIPAA-compliant clinical AI assistant; ranked first among US-based models on the NOHARM study’s real-world clinical sample.
- research_networkARISE
Independent research network that published the NOHARM clinical AI safety benchmark.
- studyNOHARM
Clinical AI safety benchmark evaluating harmful errors across 1,100 simulated scenarios in 10 specialties.
